T. Rowe Price Associates
LKFT

T. Rowe Price Associates’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

T. Rowe Price Associates’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-128,160
Closed -$5.69M – 2935
2022
Q4 		$5.69M Sell
128,160
-1,092
-0.8% -$46K ﹤0.01% 1163
2022
Q3 		$5.51M Buy
+129,252
New +$6.62M ﹤0.01% 1185

Other funds holding LKFT

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates's LKFT Position: Q1 2023 in Review

T. Rowe Price Associates sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2023, closing a stake of 128,160 shares — an estimated $5.69M sold.

T. Rowe Price Associates first reported a position in LKFT in Q3 2022 and held it in 2 quarters. The position peaked at $5.69M in Q4 2022. 75 funds tracked by Wall St. Rank hold LKFT as of Q1 2023.

  • T. Rowe Price Associates reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 128,160 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2023, an estimated $5.69M.
  • T. Rowe Price Associates first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2022 and held it in 2 quarters.
  • T. Rowe Price Associates's Lakefront Biotherapeutics American Depositary Shares position peaked at $5.69M in Q4 2022.
  • 75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.